APA (7th ed.) Citation

Hemmi, T., Ainai, A., Hashiguchi, T., Tobiume, M., Kanno, T., Iwata-Yoshikawa, N., . . . Suzuki, T. (2022). Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. Vaccine, 40(41), 5892-5903. https://doi.org/10.1016/j.vaccine.2022.08.049

Chicago Style (17th ed.) Citation

Hemmi, Takuya, et al. "Intranasal Vaccination Induced Cross-protective Secretory IgA Antibodies Against SARS-CoV-2 Variants with Reducing the Potential Risk of Lung Eosinophilic Immunopathology." Vaccine 40, no. 41 (2022): 5892-5903. https://doi.org/10.1016/j.vaccine.2022.08.049.

MLA (9th ed.) Citation

Hemmi, Takuya, et al. "Intranasal Vaccination Induced Cross-protective Secretory IgA Antibodies Against SARS-CoV-2 Variants with Reducing the Potential Risk of Lung Eosinophilic Immunopathology." Vaccine, vol. 40, no. 41, 2022, pp. 5892-5903, https://doi.org/10.1016/j.vaccine.2022.08.049.